Cisplatin-Induced Peripheral Neuropathy: An Observational Descriptive Study

Abstract

Peripheral neurotoxicity is a major adverse effect of cisplatin chemotherapy. A prospective observational study was conducted among 200 cancer patients who received cisplatin between October 2017 and March 2018 to evaluate the occurrence, causality and severity of cisplatin induced peripheral neuropathy. A suitable data collection form was used to record patient information required for the study. Peripheral neuropathy was assessed using the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE). As per the results, 19 (9.5%) patients developed peripheral neuropathy after receiving cisplatin therapy. Peripheral neuropathy was reported higher in males (84.2%) compared to females (15.7%) and more within the age group of 58-65 years (38.6%). Most of the patients developed Grade I neuropathy (84.2%), followed by Grade II neuropathy (15.7%). The study concluded that the severity of peripheral neuropathy increases with higher cumulative doses of cisplatin.

Targeting Production of Reactive Oxygen Species as an Anticancer Strategy

“…Cisplatin (Figure 3) is one of the most commonly used drugs in the chemotherapy of various types of cancer, such as testicular, ovarian, non-small-cell lung, head and neck, bladder and stomach cancer (42). However, cisplatin is also characterized by extensive toxicity, provoking side-effects such as renal damage (43), deafness (44) and peripheral neuropathy (45), limiting its overall effectiveness. Cisplatin has also been linked to significant inflammatory responses (46,47).…”